Search for a command to run...
Introduction: Antibiotic-resistant bacteria are a major health threat. While bacteriophages can target bacteria with precision, their therapeutic use is constrained by limited host range and bacterial resistance. This review highlights recent advances in engineering CRISPRCas–enhanced phages to overcome these limitations. Methods: A comprehensive literature survey was conducted using PubMed, ScienceDirect, Scopus, Web of Science, and Google Scholar to identify relevant studies on CRISPR-enhanced bacteriophages. The search employed the keywords “CRISPR,” “bacteriophages,” “CRISPRphages,” “antibiotic resistance,” “phage therapy,” “CRISPR diagnostics,” and “genome editing antimicrobials.” Only peer-reviewed English-language publications were included. Results: CRISPR-phages can eliminate resistant strains while preserving healthy microbiota. Advances in synthetic biology, host-range expansion, and delivery systems have expanded their therapeutic scope. Engineered CRISPR-phages show improved targeting precision and reduced off-target effects compared to natural phages. Discussion: Integrating CRISPR-Cas systems with bacteriophage therapy offers a powerful, targeted approach to eliminate multidrug-resistant bacteria while preserving beneficial microbiota. This programmable precision helps overcome the limitations of conventional antibiotics and natural phages. However, challenges such as optimising delivery, minimising off-target effects, preventing phage resistance, and establishing clear regulatory guidelines remain. Continued research focused on scalable production, safety validation, and combination therapy with existing antibiotics will be essential to translate CRISPR-enhanced phages into effective clinical tools against antibiotic resistance. Conclusion: CRISPR-enhanced phages offer a novel precision-medicine platform to combat multidrug-resistant infections, integrating targeted genome editing with phage therapy